Crystal form of renal outer medullary potassium channel inhibitor and preparation method of crystal form

Abstract

The invention relates to a crystal form of a renal outer medullary potassium channel inhibitor and a preparation method of the crystal form. Specifically, the invention relates to an IV crystal form of an L-tartrate of a renal outer medullary potassium channel (ROMK) inhibitor and a preparation method of the IV crystal form. The IV crystal form has good chemical stability and crystal form stability, a used crystallization solvent is low in toxicity and residue, and the IV crystal form can be better used for clinical treatment.

Description

technical field [0001] The invention relates to a crystal form of an inhibitor of a potassium channel secreted by extrarenal medulla and a preparation method thereof. Background technique [0002] Enhanced salt reabsorption by the kidneys increases the risk of high blood pressure. On the contrary, inhibiting the reabsorption function of the kidney can promote the excretion of urine and play a diuretic and hypotensive effect. Common diuretics include thiazide diuretics, which are the first-line antihypertensive drugs in the United States and mainly act on Na + -Cl transporter; Loop diuretics are more effective in patients with impaired renal function, mainly through Na + -K + -2Cl - Transport proteins do their job. But both diuretics can cause hypokalemia (symptoms: weakness, fatigue, muscle cramps, constipation, and heart rhythm problems such as irregular heartbeat), increasing the risk of cardiovascular morbidity and mortality. [0003] The renal outer medullary potas...

AI Technical Summary

Problems solved by technology

Generally speaking, amorphous pharmaceutical products have no regular crystal structure and often have other defects, such as poor product stability, difficult filtration, easy agglomeration, poor fluidity, etc.

Images